BOSTON, Dec. 4 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation , has selected experts in the fields cardiovascular, musculoskeletal, oncology, and central nervous system imaging to serve as scientific advisors. These advisors are working with the Perceptive Informatics Medical Imaging functional units to help guide clients in making key decisions regarding the imaging related aspects of clinical programs from early stage development through post- marketing studies.
“Scientific advances across a broad range of therapeutic areas are increasing the potential for medical imaging to serve as an endpoint in determining the safety and efficacy of new treatments in clinical trials,” said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International. “By combining the regulatory and drug development experience of our global medical imaging team with the specialized therapeutic area expertise of these advisors, we are helping clients to make better and more informed decisions regarding the best use of medical imaging in their development programs.”
“Our scientific advisors represent a valuable resource to clients who look to Perceptive for the medical imaging expertise to help them quickly identify the most promising imaging solutions to accelerate the drug development process,” said Todd Joron, Corporate Vice President and General Manager at Perceptive Informatics.
Perceptive Informatics’ Medical Imaging division leverages advanced technology to ensure the effective use of imaging surrogate endpoint data as well as secure data access and back-up. The Perceptive Informatics medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology.
About Perceptive Informatics, a PAREXEL Company
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(R) solution is Perceptive’s market-leading CTMS product with 26,000 users worldwide, and Perceptive’s INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Jennifer.Baird@PAREXEL.com Email: rpasso@shiftcomm.com
CONTACT: Jennifer Baird, Director of Public Relations, PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com,
Jennifer.Baird@PAREXEL.com, or Rebecca Passo, SHIFT Communications,
+1-617-779-1817, rpasso@shiftcomm.com
Web site: http://www.parexel.com/
http://www.perceptive.com/
